

# Gustavo Helguera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7903484/publications.pdf>

Version: 2024-02-01

53  
papers

3,005  
citations

218677

26  
h-index

223800

46  
g-index

60  
all docs

60  
docs citations

60  
times ranked

4830  
citing authors

#	ARTICLE	IF	CITATIONS
1	The transferrin receptor and the targeted delivery of therapeutic agents against cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 291-317.	2.4	610
2	The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. <i>Clinical Immunology</i> , 2006, 121, 144-158.	3.2	525
3	The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. <i>Clinical Immunology</i> , 2006, 121, 159-176.	3.2	462
4	Adaptive Downregulation of Mitochondrial Function in Down Syndrome. <i>Cell Metabolism</i> , 2013, 17, 132-140.	16.2	130
5	Remodeling of Kv4.3 Potassium Channel Gene Expression under the Control of Sex Hormones. <i>Journal of Biological Chemistry</i> , 2001, 276, 31883-31890.	3.4	112
6	Paclitaxel-loaded PCL-TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 113, 43-50.	5.0	101
7	Sub-Ångström cryo-EM structure of a prion protofibril reveals a polar clasp. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 131-134.	8.2	87
8	Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19322-19327.	7.1	66
9	Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. <i>Blood</i> , 2006, 108, 2745-2754.	1.4	50
10	Alternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancy. <i>FEBS Letters</i> , 2005, 579, 4856-4860.	2.8	47
11	An Antibody Recognizing the Apical Domain of Human Transferrin Receptor 1 Efficiently Inhibits the Entry of All New World Hemorrhagic Fever Arenaviruses. <i>Journal of Virology</i> , 2012, 86, 4024-4028.	3.4	47
12	Antibody-cytokine fusion proteins: applications in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 609-632.	3.1	45
13	A versatile targeting system with lentiviral vectors bearing the biotin adaptor peptide. <i>Journal of Gene Medicine</i> , 2009, 11, 655-663.	2.8	45
14	Antibody-mediated targeting of the transferrin receptor in cancer cells. <i>Boletín Médico Del Hospital Infantil De México</i> , 2016, 73, 372-379.	0.3	44
15	Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. <i>Leukemia</i> , 2009, 23, 59-70.	7.2	42
16	Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. <i>Journal of Controlled Release</i> , 2013, 171, 322-329.	9.9	42
17	Tissue-specific regulation of Ca <sup>2+</sup> channel protein expression by sex hormones. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2002, 1569, 59-66.	2.4	39
18	Conjugation of an anti-transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2995-3008.	4.1	38

#	ARTICLE	IF	CITATIONS
19	Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 991-1003.	4.2	37
20	Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 902-915.	4.1	36
21	A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. <i>BMC Cancer</i> , 2013, 13, 195.	2.6	34
22	Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. <i>Toxicology in Vitro</i> , 2013, 27, 220-231.	2.4	32
23	Binding specificity and internalization properties of an antibody-â€œavidin fusion protein targeting the human transferrin receptor. <i>Journal of Controlled Release</i> , 2007, 124, 35-42.	9.9	29
24	Antibody-Cytokine Fusion Proteins: Harnessing the Combined Power of Cytokines and Antibodies for Cancer Therapy. <i>Clinical Immunology</i> , 2002, 105, 233-246.	3.2	28
25	An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies. <i>Journal of Immunotherapy</i> , 2011, 34, 500-508.	2.4	28
26	Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1029-1040.	4.1	27
27	Changes in global gene expression in rat myometrium in transition from late pregnancy to parturition. <i>Physiological Genomics</i> , 2009, 36, 89-97.	2.3	27
28	Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. <i>Vaccine</i> , 2006, 24, 304-316.	3.8	23
29	Evaluation of cell culture in microfluidic chips for application in monoclonal antibody production. <i>Microelectronic Engineering</i> , 2016, 158, 126-129.	2.4	21
30	Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. <i>Leukemia and Lymphoma</i> , 2011, 52, 2169-2178.	1.3	20
31	Antibody-â€œCytokine Fusion Proteins for the Therapy of Cancer. , 2005, 109, 347-374.		16
32	Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. <i>Journal of Immunological Methods</i> , 2011, 368, 54-63.	1.4	14
33	Inhibition of NF- $\kappa$ B and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. <i>International Journal of Oncology</i> , 2010, 36, 1299-307.	3.3	11
34	A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 721-729.	4.1	10
35	IBCâ€™s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5â€™8, 2011, San Diego, CA. <i>MAbs</i> , 2012, 4, 153-181.	5.2	10
36	Production of monoclonal antibodies in microfluidic devices. <i>Integrative Biology (United Kingdom)</i> , 2018, 10, 136-144.	1.3	9

#	ARTICLE	IF	CITATIONS
37	Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1507-1512.	4.2	8
38	Development of image analysis software for quantification of viable cells in microchips. <i>PLoS ONE</i> , 2018, 13, e0193605.	2.5	8
39	Antibody-Based Inhibition of Pathogenic New World Hemorrhagic Fever Mammarenaviruses by Steric Occlusion of the Human Transferrin Receptor 1 Apical Domain. <i>Journal of Virology</i> , 2021, 95, e0186820.	3.4	7
40	ATP activation of plasma membrane yeast H <sup>+</sup> -ATPase shows complex kinetics independently of the degree of purification. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1993, 1153, 283-288.	2.6	6
41	Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein. <i>Cytokine</i> , 2019, 120, 220-226.	3.2	4
42	The IgE Antibody and Its Use in Cancer Immunotherapy. , 2010, , 159-183.		4
43	Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. <i>Nature Communications</i> , 2022, 13, 558.	12.8	4
44	Hydrophilic-Lipophilic Balance of Polyoxyethylene Fatty Acid Esters Nonionic Surfactants. <i>Journal of Dispersion Science and Technology</i> , 2013, 34, 716-721.	2.4	2
45	Targeting the Transferrin Receptor to Overcome Resistance to Anti-Cancer Agents. , 2008, , 13-27.		2
46	Biosimilar Monoclonal Antibodies in Latin America. , 0, , .		2
47	Large Area Microfluidic Bioreactor for Production of Recombinant Protein. <i>Biosensors</i> , 2022, 12, 526.	4.7	2
48	Phosphoryl Group Exchange between ATP and ADP Catalyzed by H <sup>+</sup> -ATPase from Oat Roots. <i>Plant Physiology</i> , 1997, 114, 1397-1403.	4.8	1
49	Bihelical waves: A novel form of eukaryotic cell motility exhibited by African trypanosomes. <i>Biophysical Journal</i> , 2009, 96, 631a.	0.5	0
50	Antibody-mediated targeting of the transferrin receptor in cancer cells. <i>Boletín Médico Del Hospital Infantil De México (English Edition)</i> , 2016, 73, 372-379.	0.0	0
51	Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis. <i>Blood</i> , 2008, 112, 4473-4473.	1.4	0
52	Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance. <i>Blood</i> , 2008, 112, 3770-3770.	1.4	0
53	Cellular and Molecular Mechanisms of Sensitivity and Resistance of Hematopoietic Malignant Cells to Treatment with ch128.1Av, An Antibody-Avidin Fusion Protein Specific for Human Transferrin Receptor 1 (CD71).. <i>Blood</i> , 2008, 112, 1608-1608.	1.4	0